Business Wire

CORSEARCH

23.5.2024 14:44:27 CEST | Business Wire | Press release

Share
Number of Active Global Trademarks to Surpass the 100 Million Mark in Just Three Years, Finds Corsearch

Corsearch, the leading provider of brand protection and trademark solutions, has today shared research forecasting that the number of active global trademarks will surpass the 100 million mark by 2026, in just two years.

Data from the Corsearch TrademarkNow platform shows that there were 83,613,385 active trademarks at the end of 2023, predicted to rise to 88,072,867 by the end of this year. Corsearch calculations forecast that by 2026, this figure will reach 100,720,928 – an increase of over 150% from the 2016 figures from a decade prior.

This growth in active trademark volumes demonstrates the increasing number of intellectual properties being developed and used by organizations across the world, in addition to a growing focus on the importance of protecting your intangible assets.

Examining 2024 filing figures, Corsearch can reveal that the country with the most active companies filing trademarks is China, followed swiftly by the USA and Brazil. The UK ranks 8th globally and, of the EU, only France features in the top ten most active filing countries.

Trademark volume rankings by originating country, 2023

1.

China

2.

USA

3.

Brazil

4.

India

5.

Turkey

6.

Mexico

7.

Japan

8.

United Kingdom

9.

Russia

10.

France

In order to support in-house counsel and expert IP advisors through this period of significant growth, Corsearch has also today announced its next-generation TrademarkNow platform. Lightning-fast AI and insights from 1,000+ sources ensure comprehensive trademark searching and monitoring – upgrades include:

  • 75% faster turnaround time for notices than other industry solutions. Automated and Expert Watch solutions offer options between AI technology to deliver efficient monitoring of trademarks in the face of expanding trademark portfolios without sacrificing accuracy, or bespoke strategies and focused insights for more complex, high-value matters
  • 40% improvement in IP legal team speeds of delivery for brand name clearance, with Corsearch LogoCheck and Name Generator tools allowing better searching of existing brand identities in combination with AI suggestions of candidate names
  • Industrial Designs can be searched faster and more accurately through new similarity algorithms and the Corsearch AI image recognition engine
  • ExaMatch search modifiers and NameCheck reporting allow for more targeted search queries and customizable reports better fit for individual needs

Viji Krishnan, President of Trademark Solutions, Corsearch, commented:

“Over the past years, the world has been waking up to the importance of trademarking intangible assets and intellectual property, and the risks of not doing so. It’s no surprise that we are only a few years away from seeing over 100 million trademarks active across the globe. It’s an optimistic sign of the intense innovation fuelling global organizations and empowering global business.

“But as with most things: the higher the volume of actively registered trademarks, the greater the potential complexity for IP professionals. We’re delighted to be launching our next-generation TrademarkNow platform to help experts in our sector cut through the noise. New AI tools will operate at the sheer scale needed to manage the size of modern trademark portfolios, effective dashboards which help prioritize work and the combined human expertise of our analysts who average over 15 years’ experience, ensures that brands uphold trademark distinctiveness.”

Notes to Editors

Methodology

Corsearch calculations are based on the data sourced from the TrademarkNow™ global trademark platform spanning all global trademark offices and registries. Where applicable, the effects of COVID on trademark filing have been accounted for.

About Corsearch:

Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521172877/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye